Department of Respiratory, Hangzhou Third People's Hospital, Hangzhou, China.
Thorac Cancer. 2022 Feb;13(3):316-321. doi: 10.1111/1759-7714.14242. Epub 2021 Nov 27.
To investigate the diagnostic performance of microRNA-21 detected in serum or sputum as a biomarker for lung carcinoma identification through pooling the open published data.
Clinical diagnostic studies related to microRNA-21 as a biomarker for lung carcinoma identification were electronically searched in the databases of Pubmed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, and Google Scholar. The data of the included studies was extracted and made pooling of diagnostic sensitivity, specificity, diagnostic odds ratio (DOR), area under the summary receiver operating characteristic curve (ROC) (AUC) for microRNA-21 expression in serum or sputum as a biomarker for lung carcinoma identification. The publication bias was evaluated by Deek's funnel plot.
Seventeen diagnostic studies were finally included and made data pooling. For the included 17 studies, 4 investigated the microRNA-21 expression in sputum and 13 studies in serum. The pooled diagnostic sensitivity and specificity were 0.73 (95% CI, 0.67-0.78) and 0.81 (95% CI, 0.75-0.85), respectively, under random effect model. The combined DOR was 9.65 (95% CI, 6.64-14.03) with the AUC of 0.84 (95% CI, 0.80-0.87). Given a pre-test probability of 50%, the post-test positive probability and post-test negative probability were 79% and 25%, respectively, by using microRNA-21 as a biomarker for lung carcinoma diagnosis. Deek's funnel was obviously asymmetry and indicated significant publication bias (p < 0.05).
MicroRNA-21 in serum or sputum was a promising biomarker for lung cancer identification with relative high diagnostic sensitivity and specificity.
通过汇集已发表的公开数据，研究血清或痰液中 microRNA-21 作为肺癌诊断标志物的诊断性能。
通过电子检索 Pubmed、EMBASE、Cochrane 图书馆、中国知网、万方和 Google Scholar 数据库，查找与 microRNA-21 作为肺癌诊断标志物相关的临床诊断研究。提取纳入研究的数据，并对血清或痰液中 microRNA-21 作为肺癌诊断标志物的诊断敏感性、特异性、诊断比值比（DOR）、汇总受试者工作特征曲线（ROC）下面积（AUC）进行汇总分析。采用 Deek's 漏斗图评估发表偏倚。
最终纳入 17 项诊断研究进行数据分析。其中 4 项研究检测了痰液中的 microRNA-21 表达，13 项研究检测了血清中的 microRNA-21 表达。在随机效应模型下，汇总的诊断敏感性和特异性分别为 0.73（95%CI，0.67-0.78）和 0.81（95%CI，0.75-0.85）。合并的 DOR 为 9.65（95%CI，6.64-14.03），AUC 为 0.84（95%CI，0.80-0.87）。在预测试概率为 50%的情况下，使用 microRNA-21 作为肺癌诊断标志物，阳性后验概率和阴性后验概率分别为 79%和 25%。Deek's 漏斗明显不对称，表明存在显著的发表偏倚（p<0.05）。
血清或痰液中的 microRNA-21 作为肺癌诊断标志物具有较高的诊断敏感性和特异性，是一种很有前途的生物标志物。
